Giannoudi Marilena, Giannoudis Peter V
Department of Cardiology, Bradford Teaching Hospitals NHS Trust, Bradford, UK.
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
EFORT Open Rev. 2022 May 31;7(6):356-364. doi: 10.1530/EOR-22-0028.
With an ever-ageing population, the incidence of hip fractures is increasing worldwide. Increasing age is not just associated with increasing fractures but also increasing comorbidities and polypharmacy. Consequently, a large proportion of patients requiring hip fracture surgery (HFS) are also prescribed antiplatelet and anti-coagulant medication. There remains a clinical conundrum with regards to how such medications should affect surgery, namely with regards to anaesthetic options, timing of surgery, stopping and starting the medication as well as the need for reversal agents. Herein, we present the up-to-date evidence on HFS management in patients taking blood-thinning agents and provide a summary of recommendations based on the existing literature.
随着全球人口老龄化,髋部骨折的发病率在不断上升。年龄增长不仅与骨折风险增加相关,还与合并症增多和多种药物联用有关。因此,很大一部分需要进行髋部骨折手术(HFS)的患者也在服用抗血小板和抗凝药物。对于这些药物如何影响手术,即麻醉选择、手术时机、停药和用药以及是否需要逆转剂等方面,仍然存在临床难题。在此,我们展示了关于服用血液稀释剂患者的HFS管理的最新证据,并根据现有文献提供了建议总结。